DK0744941T3 - Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer - Google Patents

Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer

Info

Publication number
DK0744941T3
DK0744941T3 DK95909559T DK95909559T DK0744941T3 DK 0744941 T3 DK0744941 T3 DK 0744941T3 DK 95909559 T DK95909559 T DK 95909559T DK 95909559 T DK95909559 T DK 95909559T DK 0744941 T3 DK0744941 T3 DK 0744941T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
finely divided
preparing finely
divided pharmaceutical
extrusion
Prior art date
Application number
DK95909559T
Other languages
English (en)
Inventor
Pramod K Gupta
Jacqueline E Briskin
Claud Loyd
Robert W Kohler
Susan J Semla
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0744941T3 publication Critical patent/DK0744941T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95909559T 1994-02-16 1995-02-14 Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer DK0744941T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19702594A 1994-02-16 1994-02-16
PCT/US1995/001943 WO1995022319A1 (en) 1994-02-16 1995-02-14 Process for preparing fine particle pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0744941T3 true DK0744941T3 (da) 2003-09-29

Family

ID=22727703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95909559T DK0744941T3 (da) 1994-02-16 1995-02-14 Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer

Country Status (11)

Country Link
US (1) US6063313A (da)
EP (1) EP0744941B1 (da)
JP (1) JP4040084B2 (da)
AT (1) ATE241962T1 (da)
CA (1) CA2182282C (da)
DE (1) DE69530973T2 (da)
DK (1) DK0744941T3 (da)
ES (1) ES2199981T3 (da)
MX (1) MX9603480A (da)
PT (1) PT744941E (da)
WO (1) WO1995022319A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531277A1 (de) 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
FR2753904B1 (fr) * 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DK1073513T3 (da) * 1998-04-24 2003-12-22 Basf Corp Forbedret ekstruderingsproces
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US6365216B1 (en) 1999-03-26 2002-04-02 The Nutrasweet Company Particles of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002024174A2 (en) * 2000-09-22 2002-03-28 Galephar M/F Sustained release composition containing clarithromycin
FR2816507B1 (fr) 2000-11-16 2003-02-28 Ethypharm Lab Prod Ethiques Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
EP1392272B1 (en) 2001-05-11 2014-08-06 Merrion Research III Limited Permeation enhancers
US20030203019A1 (en) * 2002-04-30 2003-10-30 Cornelius John Mark Coated conditioners for use in foods and pharmaceuticals
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1594470A4 (en) * 2003-02-19 2007-10-17 Biovail Lab Int Srl QUICK ABSORPTION 5-HT SELECTIVE AGONIST FORMULATIONS
EP1638529B1 (en) 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
RU2517135C2 (ru) 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
EP2516494B1 (en) * 2009-12-23 2016-06-01 Essilor International (Compagnie Générale D'Optique) Method of converting a polymerizable composition into thermoplastic polyurethane of improved yellowness index and article obtained by this method
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB757165A (en) * 1953-10-30 1956-09-12 Abbott Lab Compositions of erythromycin for combating bacterial infections
US4374082A (en) * 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
IT1226549B (it) * 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
FR2663818B1 (fr) * 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5292900A (en) * 1992-12-18 1994-03-08 Abbott Laboratories O-substituted N-hydroxyurea derivatives

Also Published As

Publication number Publication date
MX9603480A (es) 1997-12-31
ES2199981T3 (es) 2004-03-01
US6063313A (en) 2000-05-16
ATE241962T1 (de) 2003-06-15
CA2182282A1 (en) 1995-08-24
JP4040084B2 (ja) 2008-01-30
WO1995022319A1 (en) 1995-08-24
DE69530973D1 (de) 2003-07-10
EP0744941A1 (en) 1996-12-04
JPH09509176A (ja) 1997-09-16
CA2182282C (en) 2006-04-18
EP0744941B1 (en) 2003-06-04
DE69530973T2 (de) 2004-05-19
PT744941E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
DK0744941T3 (da) Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer
ES524518A0 (es) Un procedimiento para preparar un agente anti-inflamatorio
MX9602515A (es) Procedimiento para preparar formas de dosis farmaceuticas de substancias hidrofobicas.
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
EP1208846A3 (en) Non-aqueous polar aprotic peptide formulations
HUT39419A (en) Process for preparing tetraline derivatives
UA42795C2 (uk) Протизапальний засіб для зовнішнього застосування, що містить німесулід, і спосіб його одержання
IL163985A0 (en) Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulation
HUT63163A (en) Process for producing anxiety relieving bis-azabicyclo compounds and pharmaceutical compositions comprising same as active ingredient
ATE269057T1 (de) Arzneizubereitungen und deren herstellungsverfahren
NO303715B1 (no) Stabilt, vandig apparat
ZA200409401B (en) Method for producing steroid crystals, crystals obtained by said method and their use in pharmaceutical formulations.
YU10599A (sh) Amorfni benzotiofeni, postupak dobijanja istih i njihova farmaceutska formulacija
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
HUT46364A (en) Process for producing 1,12-dihydroxy-1,6,12,13-tetraaza-dicyclodocosane-2,5,13,16-tetron and pharmaceutical compositions comprising this compound as active ingredient
HUT45502A (en) Process for producing new 2,6-diamino-3-(halogen-benzyl)-pyridines and pharmaceutics comprising the same as active ingredient
CA2009090A1 (en) Process for producing solid pharmaceutical preparations
AU1167097A (en) 18-methyl 16-methylene 19-nor pregnane derivatives as progestins, pharmaceutical compositions containing them and process for the preparation thereof
HUP9702465A3 (en) Epimers of (22rs)-n-(1,1,1,-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5alfa-androst-1-ene-17beta-carboxamide, process for producing them and pharmaceutical compositions containing the same
AU7189991A (en) New derivatives of 1,3,5-triamino-2,4,6-triiodobenzene and method for the preparation thereof
JPS52138751A (en) Method and apparatus of crush clearance regulation
IT8321524A0 (it) Processo per la preparazione di delta 5-steroidi da steroidi 5,7-dienici.
HK1004660A1 (en) Composition for treating hyperosteogeny and process for the preparation thereof
ITMI912324A1 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche.